CA
NZ
UK
AU
IND
US
This significant growth is driven primarily by a 12% increase in its domestic core business, alongside a remarkable 59% surge in international revenue. As the company continues to establish itself in competitive markets, this financial turnaround offers a positive outlook for investors, especially with …
Micron’s shares slipped modestly while the broader memory‑chip market tumbled, with SK Hynix delivering a 10% plunge that underscored the sector’s fragility. SanDisk and Western Digital both saw sharp declines, dragging down related equities and stoking risk‑averse sentiment among investors. The selloff reflects a …
LifeStance Health Group, Inc. (NASDAQ: LFST) achieved a significant milestone by reporting second-quarter revenue of $435.4 million, representing a 26% increase from $345.3 million in the same period last year. The earnings per share (EPS) came in at $0.06, surpassing analysts' expectations of $0.04. …
SpaceX shares have climbed 1.7% to $116.83 as traders react positively to the expiration of a key lock-up provision. This move suggests investors are betting on a potential rebound, influencing market dynamics amid an overall decline of 28.6% year-to-date.Key HighlightsThis expiration allows previously restricted …
Lineage Cell Therapeutics (NYSE American: LCTX) disclosed second‑quarter results showing revenue of $1.1 million, representing a net decrease of $1.7 million compared with the same period last year. The company’s cash, cash equivalents and marketable securities totaled $50.8 million, a level that extends the …
This impressive growth showcases the company's ability to capitalize on its expansive business segments, particularly in AI and Connectivity, allowing it to bolster its market position even amid broader sector uncertainties.
The company also disclosed a net loss of $44.8 million, up $2.1 million from the same period a year earlier, while cash and marketable securities stood at $228.0 million. A strong manufacturing success rate of 97% for its dual‑targeting CAR‑T candidate ronde‑cel, coupled with …
Insulet Corporation has significantly revised its revenue outlook for 2026, now projecting growth between 20% and 22%. This downward adjustment stems from lower than expected retention and utilization rates among Type 2 diabetes patients, particularly during critical early therapy phases. The company's approach is …
American Healthcare REIT, Inc. achieved impressive quarterly results, reporting an earnings per share (EPS) of $0.54 for the quarter ended June 30, 2026. With annual market capitalization now at approximately $11.4 billion, this strong earnings announcement signals a vital growth trajectory for American Healthcare …
Arcutis Biotherapeutics has reported a strong second quarter for 2026, highlighting a 59% increase in revenue that signals significant market traction. This growth reflects heightened demand for the company's dermatological products amid an expanding pipeline. The achievement of profitability represents a critical milestone, affecting …
Please wait processing your request...